The TIOB - Collection of Patients' Biospecimens for Analysis of Immunological and Molecular Biomarkers.
Launched by BAYLOR RESEARCH INSTITUTE · May 11, 2022
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
The Texas Immuno-Oncology Biorepository (TIOB) is a clinical trial focused on collecting and storing samples from cancer patients. These samples include tissue, blood, urine, and stool, which will help researchers better understand the immune response and other important factors related to cancer. The goal is to gather detailed information from a diverse group of patients as they receive standard cancer treatments or FDA-approved immunotherapy, which is a type of treatment that helps the immune system fight cancer.
To participate, you need to be an adult who understands and agrees to provide written consent for the study. You might be eligible if your doctor suspects you are at risk for cancer or if you have a confirmed cancer diagnosis. Participants can expect to provide samples over time and share their medical information, contributing to important research that could benefit future cancer treatments. It's essential to know that if you're not comfortable donating blood or providing tissue samples, you may not be able to participate in this study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Understand and willingness to sign written informed consent method.
- • Patients who are suspected by a physician of being at risk for developing cancer.
- • Patients with confirmed or clinically suspected malignancy by a physician. This includes but is not limited to candidates for immunotherapy, surgical candidates, patients receiving Standard of Care drugs, immunotherapy drugs, participating on a clinical trial with immunotherapy drugs, patients who have received immunotherapy drugs in the past, patients with any other approved or investigational disease management.
- Exclusion Criteria:
- • Patients unwilling to donate blood
- • Patients unwilling to provide informed consent for the collection of fresh or archived tumor tissue.
About Baylor Research Institute
Baylor Research Institute (BRI) is a leading clinical research organization affiliated with Baylor Scott & White Health, dedicated to advancing medical knowledge and improving patient care through innovative research initiatives. With a focus on translational medicine, BRI conducts a wide range of clinical trials across various therapeutic areas, including cardiovascular, oncology, and neurology. The institute is committed to fostering collaborative partnerships with academic institutions, industry leaders, and healthcare professionals to enhance the development of novel therapies and interventions. Through rigorous scientific methodology and ethical standards, Baylor Research Institute strives to contribute significantly to the advancement of healthcare and to provide patients with access to cutting-edge treatments.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dallas, Texas, United States
Patients applied
Trial Officials
Ronan Kelly, MD
Principal Investigator
Baylor Scott & White Research Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials